Alliance for Aging Research

Filing Period

Jul 1, 2011 to Jun 30, 2012

Signed

Feb 1, 2013

Return Version

2011v1.2

Gross Receipts

$1,857,954

Mission

Major Activities

Activity 2

Communications: the alliance for aging research disseminates information on aging-related health topics, conducts surveys, and provides online web-based information on issues impacting the aging community.

Activity 3

Public policy: the alliance for aging research partners with the government, private and corporate policy makers, and other nonprofit organizations to promote research on aging related topics. * health programs: www.silverbook.org is now more than 5 years old and is showing its age! In order to offer more intuitive browsing, additional search features, improved administrative control, and a more modern look, we are currently undergoing a redesign. We are working with basis branding to design and launch this new site sometime this summer. We will tie the marketing and promotion of our latest silver book on vision loss to the promotion of this website. We will also let interested parties know about the updated resource via facebook, twitter, e-mail blasts, and other social marketing. * health programs: while many older adults are healthy and independently pursue active lifestyles, others are suffering with persistent pain often associated with disease, physical disability and psychosocial complications. Statistics regarding the prevalence of pain among older adults vary widely, ranging from 25% to 80%. Persistent pain is estimated to occur in 45% to 80% of nursing home residents, and in 25% to 50% of community-dwelling adults. The alliance is grateful to announce a commitment from pfizer inc. To develop a silver book on persistent pain. As with other silver books, the volume on persistent pain will include the most up-to-date information in one easy-to-use, well-referenced resource. It will be sent to policy makers, scientists and practitioners at no cost to them; and will promote in-depth policy discussions that encourage investments in innovation in the field of diagnosis, prevention, and management.* alliance leads patient advocacy group letter on nih drug repurposing pilot: on may 3 the secretary of health and human services launched a partnership between the nih's national center for advancing translational sciences (ncats) and astrazeneca, eli lilly and pfizer to investigate a set of existing drugs that may be repurposed to treat diseases other than those for which they were previously tested. In addition to launching the partnership, hhs also announced the availability of $20 million in funding that will be made available for grants submitted as part of this new program. In order to express broad support from the alzheimer's community for the use of this program to explore the potential of compounds that could potentially affect ad, the alliance for aging research wrote a letter to the acting director of ncats and secured 16 other endorsements from outside groups. Since submitting this letter the number of compounds available for testing in this program has more than doubled and ncats gained five additional industry partners-abbott, bristol-myers squibb, glaxosmithkline, janssen, and sanofi. * alliance represented at first-ever fda patient network meeting on risk-benefit analysis: in may 18 the food and drug administration (fda) held an inaugural patient network annual meetingtitled "patient input into fda benefit-risk decision-making: opportunities and challenges." the meeting was convened to discuss opportunities growing out of the current user fee agreements for fda to enhance its regulatory decision-making through the inclusion of patients and patient advocate groups during benefit-risk assessments of drugs and devices.the meeting included a series of presentations, exercises, and panel discussions to facilitate a conversation with the patient community about how patients define and perceive benefits and risks related to medical products. One such panel included cynthia bens, the alliance's director of public policy. Her remarks stressed the importance of considering disease severity and unmet need in fda's risk-benefit decision-making on early stage treatments for alzheimer's. Ms. Bens also highlighted that for chronic, progressive diseases like alzheimer's the views of caregivers on benefit and risk must be taken in

Filer

EIN

54-1379174